
Shanghai Henlius Biotech Investor Relations Material
Latest events

H2 2024
24 Mar, 2025

H1 2024
25 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Shanghai Henlius Biotech Inc
Access all reports
Shanghai Henlius Biotech Inc is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of biologic drugs, particularly biosimilars and monoclonal antibody therapies. The company’s product portfolio addresses a range of therapeutic areas, including oncology, autoimmune diseases, and infectious diseases. Henlius operates advanced manufacturing facilities and research centers, employing innovative biotechnology to support its drug development pipeline and expand access to biologic treatments. The company is headquartered in Shanghai, China, and its shares are listed on the HKEX.
Key slides for Shanghai Henlius Biotech Inc


H2 2024
Shanghai Henlius Biotech Inc


H2 2024
Shanghai Henlius Biotech Inc
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
2696
Country
🇭🇰 Hong Kong